Presentation is loading. Please wait.

Presentation is loading. Please wait.

PAH Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy Salman Bin AbdulAziz University College Of Pharmacy.

Similar presentations


Presentation on theme: "PAH Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy Salman Bin AbdulAziz University College Of Pharmacy."— Presentation transcript:

1 PAH Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy Salman Bin AbdulAziz University College Of Pharmacy

2 R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of breath. She could walk only 10–20 ft at baseline and is now short of breath at rest. Her arterial blood gas is pH 7.31/Pco2 65/Po2 53/85% O2 saturation. She has three-pillow orthopnea and 3+ pitting edema in her lower extremities. Case 1 Medical history significant only for AF. Computerized tomographic angiography shows that her pulmonary artery trunk is substantially enlarged, with a mean pressure of 56 mm Hg. On Examnination Echocardiography shows right atrial and ventricular hypertrophy. Chest radiography detects prominent interstitial markings.

3 laboratory test BUN 21 mg/dL, SCr 1.2 mg/dL, AST 145 IU/L, ALT 90 IU/L, INR 2.1, and PTT 52 seconds; vital signs include BP 108/62 mm Hg and HR 62 beats/minute. Home medications warfarin 2.5 mg/day, ipratropium 2 puffs every 6 hours, salmeterol 2 puffs 2 times/day, and diltiazem 480 mg/day. Her diagnosis is IPAH. Define ! PAH (Pulmonary Arterial Hypertension) Types of PAH ? Complications of PAH include ? 1. right ventricular dysfunction leading to right heart failure. 2. Blood clots 3. Irregular heartbeats (arrhythmias)

4 The ( S, O ) ( signs and symptoms ) part of SOAP in this patient is ?  Subjective increasing symptoms of fatigue and shortness of breath. She could walk only 10–20 ft at baseline and is now short of breath at rest  Objective arterial blood gas is pH 7.31/Pco2 65/Po2 53/85% O2 saturation. She has three-pillow orthopnea and 3+ pitting edema in her lower Medical history significant only for AF. Computerized tomographic angiography shows that her pulmonary artery trunk is substantially enlarged, with a mean pressure of 56 mm Hg On Examnination Echocardiography shows right atrial and ventricular hypertrophy. Chest radiography detects prominent interstitial markings. Medications warfarin 2.5 mg/day, ipratropium 2 puffs every 6 hours, salmeterol 2 puffs 2 times/day, and diltiazem 480 mg/day.

5 MCQ All the following procedures used to diagnose R.W condition except I.Electrocardiogram (ECG ), Echocardiography,hemodynamic changes II.Chest radiography III.Physical examination IV.Spirometry

6 Hemodynamic Parameters

7 MCQ All the following procedures used to diagnose R.W condition except I.Electrocardiogram (ECG ), Echocardiography,hemodynamic changes II.Chest radiography III.Physical examination IV.Spirometry Complete Patients with PAH, Chest radiography shows ? Enlarged pulmonary arteries and diminished peripheral pulmonary vascular Patient with PAH, physical examination shows ?

8

9 R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of breath. She could walk only 10–20 ft at baseline and is now short of breath at rest. Her arterial blood gas is pH 7.31/Pco2 65/Po2 53/85% O2 saturation. She has three-pillow orthopnea and 3+ pitting edema in her lower extremities. Question: According to WHO classification,this patient has I.Class I PAH II.Class II PAH III.Class III PAH IV.Class IV PAH

10 Functional class I–II, ambulated 380 m or greater (or 1250 ft) during 6- minute walk test,

11 Functional Classification A.Class I- Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnoea or fatigue, chest pain, or near syncope. B. Class II- patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnoea or fatigue, chest pain, or near syncope. C. Class III- patients with pulmonary hypertension resulting in marked. Limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnoea, fatigue, and chest pain or near syncope. D. Class IV -patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. these patients manifest signs of right heart failure. Dyspnoea and /or fatigue may be present even at rest. Discomfort is increased by any physical activity

12 R.W. is a 38-year-old obese woman who presents with increasing symptoms of fatigue and shortness of breath. She could walk only 10–20 ft at baseline and is now short of breath at rest. Her arterial blood gas is pH 7.31/Pco2 65/Po2 53/85% O2 saturation. She has three-pillow orthopnea and 3+ pitting edema in her lower extremities. Question: According to WHO classification,this patient has I.Class I PAH II.Class II PAH III.Class III PAH IV.Class IV PAH

13 In PAH patient like R.W, goals of therapy include the following except ? I.Curing PAH II.Relieve acute dyspnea symptoms. III.Improve exercise capacity/quality of life and prevent death.

14 In PAH patient like R.W, goals of therapy include the following except ? I.Curing PAH II.Relieve acute dyspnea symptoms. III.Improve exercise capacity/quality of life and prevent death. Goals of therapy I.Relieve acute dyspnea symptoms. II.Improve exercise capacity/quality of life and prevent death.

15 Question: How to assess the response to the treatment of mr R.W. Condition A.functional class determination ( WHO classification for PAH) B.6 min walk test (every 4–6 Months) C.Chest Xray D.A and B E.All of the above

16 Question: How to assess the response to the treatment of mr R.W. Condition A.functional class determination ( WHO classification for PAH) B.6 min walk test (every 4–6 Months) C.Chest Xray D.A and B E.All of the above

17 What are the Satisfactory condition in a patient with PAH ? I. Functional class I–II, II. ambulated 380 m or greater or 1250 ft) during 6-minute walk test, III. CI of 2.2 L/minute/m2 or greater IV. and mPAP less than 12 mm Hg

18 What are the Satisfactory condition in a patient with PAH ? I. Functional class I–II, II. ambulated 380 m or greater or 1250 ft) during 6-minute walk test, III. CI of 2.2 L/minute/m2 or greater IV. and mPAP less than 12 mm Hg

19 increasing symptoms of fatigue and shortness of breath. She could walk only 10–20 ft at baseline and is now short of breath at rest. Her arterial blood gas is pH 7.31/Pco2 65/Po2 53/85% O2 saturation. She has three-pillow orthopnea and 3+ pitting edema in her lower extremities. laboratory test BUN 21 mg/dL, SCr 1.2 mg/dL, AST 145 IU/L, ALT 90 IU/L, INR 2.1, and PTT 52 seconds; vital signs include BP 108/62 mm Hg and HR 62 beats/minute. Home medications warfarin 2.5 mg/day, ipratropium 2 puffs every 6 hours, salmeterol 2 puffs 2 times/day, and diltiazem 480 mg/day. Her diagnosis is IPAH. Case Remaining part

20 Question: Based on the options below, which one of the following is the best evidence-based management strategy? A. Increase diltiazem to 600 mg/day. B. Start sildenafil 20 mg 3 times/day. C. Start epoprostenol 2 ng/kg/minute. D. Start bosentan 62.5 mg 2 times/day.

21

22

23

24

25 Question: Based on the options below, which one of the following is the best evidence-based management strategy? A. Increase diltiazem to 600 mg/day. B. Start sildenafil 20 mg 3 times/day. C. Start epoprostenol 2 ng/kg/minute. D. Start bosentan 62.5 mg 2 times/day. - She is taking a considerable dose of diltiazem, and her HR likely will not tolerate further increases in therapy. - bosentan is an attractive oral option to manage her PAH, her liver enzymes are elevated more than 3 times the upper limit of normal - Because this patient is currently in functional class IV with symptoms at rest, epoprostenol is indicated for a survival benefit.

26 Adverse effects of epoprostenol ? Adverse effects of CCB ? When treating a patient with PAH, we select CCB agent on the basis of HR at baseline If tachycardic, choose …………………. If bradycardic, choose ………….., ………….. True or false CCB in PAH should be used empirically without postive response to acute vasodilatory response testing! Bosentan belongs to which class ? What monitoring parameters should be taken care of when starting patient on bosentan Sildenafil and Tadalafil adverse effects and mention a difference between the two drugs


Download ppt "PAH Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy Salman Bin AbdulAziz University College Of Pharmacy."

Similar presentations


Ads by Google